(2021) The clinical impact of quantitative cell-free dna, kras, and braf mutations on response to anti-egfr treatment in patients with metastatic colorec-tal cancer. Current Pharmaceutical Design. pp. 942-952. ISSN 13816128 (ISSN)
Full text not available from this repository.
Abstract
Colorectal cancer (CRC) is one of the most common leading causes of cancer death in the world. Al-though EGFR inhibitors have established efficacy in metastatic colorectal cancer (mCRC), some patients do not respond to this treatment. The EGFR inhibitors' failure and acquired resistance are partly due to KRAS and BRAF mutations. Thus, prognostic biomarkers that help to select eligible patients are highly in demand. To improve patient selection, assessment of mutational status in circulating cell free DNA (cfDNA), which possibly represents the dynamicity of tumor genetic status better than tumor tissue, could be advantageous. This review summarizes the current knowledge of the prognostic value of cfDNA in patients with mCRC treated with EGFR inhibitors with emphasis on the clinical importance of identification of KRAS and BRAF mutations. © 2021 Bentham Science Publishers.
| Item Type: | Article |
|---|---|
| Keywords: | BRAF, Colorectal, EGFR, KRAS, cancer, cell-free DNA |
| Page Range: | pp. 942-952 |
| Journal or Publication Title: | Current Pharmaceutical Design |
| Volume: | 27 |
| Number: | 7 |
| Identification Number: | 10.2174/1381612826666201007163116 |
| ISSN: | 13816128 (ISSN) |
| Depositing User: | پریسا مرادی |
| URI: | http://eprints.thums.ac.ir/id/eprint/3468 |
Actions (login required)
 |
View Item |